Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Purchases 250,000 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock in a transaction dated Wednesday, June 24th. The shares were purchased at an average price of $8.00 per share, with a total value of $2,000,000.00. Following the completion of the transaction, the director directly owned 18,379,186 shares in the company, valued at approximately $147,033,488. This represents a 1.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.00 per share, for a total transaction of $199,200.00.
• On Tuesday, June 23rd, Yusheng Han acquired 5,990 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han acquired 104,650 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $7.45 per share, with a total value of $779,642.50.
• On Tuesday, June 16th, Yusheng Han bought 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han bought 210,000 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $9.25 per share, for a total transaction of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Price Performance

Shares of Burning Rock Biotech stock opened at $8.96 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.05 and a quick ratio of 2.81. The business’s 50 day simple moving average is $12.79 and its two-hundred day simple moving average is $20.08. The stock has a market capitalization of $94.26 million, a P/E ratio of -10.93 and a beta of 1.33. Burning Rock Biotech Limited Sponsored ADR has a one year low of $3.22 and a one year high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last posted its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.29) by $2.09. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%. The company had revenue of $15.66 million during the quarter, compared to analyst estimates of $19.21 million.

Wall Street Analyst Weigh In

BNR has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BNR. Crcm LP boosted its position in Burning Rock Biotech by 13.8% in the third quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares during the last quarter. Prospera Financial Services Inc increased its position in shares of Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after purchasing an additional 6,430 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Burning Rock Biotech in the 4th quarter worth approximately $220,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after purchasing an additional 4,290 shares during the period. 30.03% of the stock is owned by hedge funds and other institutional investors.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.